Withdrawal of non-binding proposal

26^th Aug 2015

In the Company’s announcement of the conclusion of its strategic review released on 18 August, 2015, reference was made to a non-binding preliminary proposal of US$110 million for the Company’s Point-of-Care business. That proposal has now been withdrawn.

The proposals referenced in the Company’s announcements released on 24 August, 2015 are not affected.

Back to Listing

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF launches FDA CLIA-waived β-ketone and glucose POC analyzer to U.S. market

New handheld STAT-Site WB ensures reliable and efficient analysis from whole blood

Supporting reduction of anemia in developing regions in South America

Symposium highlights successful use of EKF’s Hemo Control hemoglobin analyzer in extreme environmental conditions

MEDLAB Dubai - Feb 2020

"The world's largest lab expo" - Medlab Middle East is a leading laboratory and flagship exhibition and Conference spanning across Middle East, Asia and West Europe.

AIM Awards 2019

EKF Diagnostics was delighted to win the AIM Transaction of the Year Award at the AIM Awards 2019.

New R&D facility in Head Office

Special Projects Laboratory opened in EKF’s Cardiff HQ to develop new applications in non-core markets and support other global diagnostics R&D facilities